European Medicines Agency

ema.europa.eu Imported from official source

European Union body; safety publications from its own official source.

Publications 20

  1. EU recommendations for 2026/2027 seasonal flu vaccine composition

    The recommendations were updated and published on the following dates: 17 November 2026: to include a recommendation for mRNA (nucleic acid) influenza vaccines. Annex I…

    Announcement Safety
  2. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2026

    Seven new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended seven medicines for approval at its November 2026 meeting.The committee…, CHMP statistics Key figures ...

    Announcement Safety
  3. Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 3-5 November 2026

    CVMP opinions on veterinary medicinal products Further to the re-examination of the opinion adopted by the Committee during its June 2026 meeting, the Committee adopted a…

    Announcement Safety
  4. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 26 - 29 October 2026

    PRAC starts review of depression and anxiety medicine Deanxit (flupentixol/melitracen)PRAC has started a review of Deanxit, a fixed-dose combination medicine for treating…, Agenda Agenda of the PRA...

    Announcement Safety
  5. EMA closed on All Souls' Day, 2 November

    EMA’s office is closed on Monday 2 November, to mark All Souls' Day. The office reopens at 08:30 on Tuesday 3 November.The product emergency hotline is available outside…

    Announcement
  6. AMA and EMA issue joint guidance on Ebola vaccine development

    EMA’s Emergency Task Force (ETF) and the African Medicines Agency (AMA) have published a joint position paper to support the timely start of clinical trials for potential…

    Announcement Safety
  7. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2026

    Six new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended six medicines for approval at its October 2026 meeting.Rasonque (daraxonrasib)…, CHMP statistics Key fig...

    Announcement Safety
  8. EMA recommends authorisation of Rasonque for metastatic pancreatic cancer

    EMA’s human medicines committee (CHMP) has recommended granting a marketing authorisation in the European Union for Rasonque (daraxonrasib), an oral treatment for adults with…

    Announcement Safety
  9. Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 6-8 October 2026

    CVMP opinions on veterinary medicinal productsThe Committee adopted a positive opinion, in exceptional circumstances, for a marketing authorisation for Bovilis Lumpyvax (lumpy…

    Announcement Safety
  10. Clinical trial applications advice pilot becomes permanent

    The Accelerating Clinical Trials in the EU (ACT EU) advice pilot, which helps sponsors prepare clinical trial applications, will become a permanent initiative from January 2027.…

    Announcement Safety 2 versions
  11. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28 September - 1 October

    At its monthly meeting, EMA’s safety committee (PRAC) carried out its broad range of responsibilities to manage the safety of medicines, including the assessment of safety…, Agenda Agenda of t...

    Announcement Safety 2 versions
  12. Advice on ‘end-of-year’ submission dates for type I variations in 2026

    Marketing authorisation holders wishing to receive an outcome in 2026 should submit type IA annual updates, individual type IA and type IAIN variations, and super-groupings…

    Announcement Safety
  13. EMA Management Board: highlights of September 2026 meeting

    Mid-year report 2026 from the Executive DirectorEMA presented results and achievements of its operations for the first half of 2026 to the Management Board. Between January and…

    Announcement
  14. Global regulators call for advancing alternatives to animal testing across the medicine lifecycle

    EMA has endorsed a joint statement from the International Coalition of Medicines Regulatory Authorities (ICMRA) calling on medicine developers, manufacturers, regulators and…

    Announcement Safety Source page stopped responding
  15. Executive Director speech at EMA women’s health multi-stakeholder workshop

    Amsterdam, 28 September 2026Check against delivery (The published text is based on the prepared speech. Minor differences may have occurred during delivery)Good morning,…

    Announcement Source page stopped responding
  16. Women are missing from medicines development: EMA’s roadmap for change

    By the end of 2026, EMA will develop a regulatory roadmap to help drive decisive change on how women’s health is considered across medicines development and regulation. This…, Women are still missi...

    Announcement Safety Source page stopped responding
  17. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2026

    12 new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended 12 medicines for approval at its September 2026 meeting.The committee recommended…, CHMP statistics Key f...

    Announcement Safety
  18. Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 8-10 September 2026

    CVMP opinions on veterinary medicinal products The Committee adopted a positive opinion for a marketing authorisation for Cirbloc, for the active immunisation of pigs from…

    Announcement Safety
  19. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 31 August - 3 September 2026

    Review will assess risk of low blood phosphate levels and related bone problems with injectable iron medicinesEMA’s safety committee, PRAC, has started a review of injectable…, Agenda Agenda of the...

    Announcement Safety Source page stopped responding
  20. New EU supply chain to end Visudyne shortage

    A new supply chain for Visudyne (verteporfin) has been put in place in the European Union (EU), marking an important step towards resolving a long-standing shortage of the…, This situation shows th...

    Announcement Safety

Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.